Thilo Schroeder Biography and Net Worth

Director of Revolution Medicines

Thilo Schroeder, Ph.D. is a Partner at Nextech Invest and has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies.

Thilo has been a leading investor in several precision medicine oncology companies and is a board member of PMV Pharma, Circle Pharma, MOMA Therapeutics, Silverback Therapeutics and Black Diamond Therapeutics (BDTX). Past board seats include Blueprint Medicines (BPMC), Peloton Therapeutics (acquired by Merck), IDEAYA Bioscience (IDYA) and ImaginAb.

Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology now commercialized by Molecular Partners (SWX:MOLN). He also holds a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.

What is Thilo Schroeder's net worth?: The estimated net worth of Thilo Schroeder is at least $78.31 million as of December 5th, 2024. Dr. Schroeder owns 2,096,612 shares of Revolution Medicines stock worth more than $78,308,458 as of March 29th. This net worth evaluation does not reflect any other assets that Dr. Schroeder may own. Learn More about Thilo Schroeder's net worth.
How do I contact Thilo Schroeder?: The corporate mailing address for Dr. Schroeder and other Revolution Medicines executives is 700 Saginaw Drive, Redwood City CA, 94063. Revolution Medicines can also be reached via phone at 650-481-6801 and via email at ir@revmed.com. Learn More on Thilo Schroeder's contact information.
Has Thilo Schroeder been buying or selling shares of Revolution Medicines?: Thilo Schroeder has not been actively trading shares of Revolution Medicines during the last ninety days. Most recently, on Thursday, December 5th, Thilo Schroeder bought 1,304,347 shares of Revolution Medicines stock. The stock was acquired at an average cost of $46.00 per share, with a total value of $59,999,962.00. Following the completion of the transaction, the director now directly owns 2,096,612 shares of the company's stock, valued at $96,444,152. Learn More on Thilo Schroeder's trading history.
Who are Revolution Medicines' active insiders?: Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?: In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 23 times. They sold a total of 241,280 shares worth more than $11,237,223.60. The most recent insider tranaction occured on March, 17th when insider Mark A Goldsmith sold 11,738 shares worth more than $458,251.52. Insiders at Revolution Medicines own 8.0% of the company. Learn More about insider trades at Revolution Medicines.
Information on this page was last updated on 3/17/2025.

Thilo Schroeder Insider Trading History at Revolution Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2024	Buy	1,304,347	$46.00	$59,999,962.00	2,096,612
3/10/2023	Buy	100,000	$20.46	$2,046,000.00	1,553,134
3/7/2023	Buy	550,000	$22.00	$12,100,000.00	1,453,134
3/28/2022	Buy	725	$24.71	$17,914.75
3/25/2022	Buy	42,000	$24.79	$1,041,180.00
3/23/2022	Buy	53,118	$23.72	$1,259,958.96
3/21/2022	Buy	75,731	$20.74	$1,570,660.94
3/18/2022	Buy	82,200	$20.30	$1,668,660.00
3/11/2022	Buy	3,110	$20.93	$65,092.30
3/9/2022	Buy	39,600	$20.07	$794,772.00
3/7/2022	Buy	103,005	$18.39	$1,894,261.95
3/4/2022	Buy	56,300	$17.69	$995,947.00
3/2/2022	Buy	116,290	$18.94	$2,202,532.60
2/18/2022	Buy	400,000	$17.00	$6,800,000.00
2/8/2022	Buy	300,000	$45.00	$13,500,000.00

Thilo Schroeder Buying and Selling Activity at Revolution Medicines

Revolution Medicines Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $37.35

$37.03

$38.11

50 Day Range

MA: $40.32

$36.82

$44.25

2 Week Range

Now: $37.35

$29.55

$62.40

Volume

833,196 shs

Average Volume

1,375,673 shs

Market Capitalization

$6.94 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46